Below are some of the key findings from this cerebral palsy drugs market research report

The global cerebral palsy drugs market is expected to grow at a CAGR of more than 5% during the forecast period

Cerebral palsy treatment industry growth is expected to accelerate over the next five years, driven by rising incidences of cerebral palsy across the globe which is fueling the demand of medications for cerebral palsy treatment. Cerebral palsy is considered as one of the most common forms of motor disorder in early childhood. Cerebral palsy (CP) is a group of disorders that affect movement, muscle tone, and coordination and is caused due to cerebral damage during or within five years of birth. According to the CDC, the worldwide prevalence of cerebral palsy is between 1.5 to more than 4 for every 1,000 live births. The lack of proper pre-natal care may increase the chances of children developing cerebral palsy and it is becoming quite widespread in both developed and developing countries which will contribute to the growth of the market.  Technavio's cerebral palsy treatment industry analysis reveals promising markets around the world.

See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from this report.

Get a free sample now!

The Americas dominated the cerebral palsy drugs market by region

The global cerebral palsy treatment market was dominated by the Americas with more than half of the worldwide market share, followed by EMEA and APAC. In addition, the Americas will drive around 50% of the growth for the global cerebral palsy treatment industry, while EMEA and APAC are also predicted to contribute about one-fourth each to the incremental growth in the forecast period. The global cerebral palsy treatment market will witness APAC registering the fastest rate of growth during the forecast period, while the Americas will generate a higher incremental growth than EMEA region.

Allergan, GlaxoSmithKline, and Johnson & Johnson are the leading cerebral palsy therapeutic companies

The global cerebral palsy treatment market is forecasted to become moderately concentrated with the presence of a few established and large cerebral palsy therapeutic companies who offer medications for cerebral palsy such as anticholinergics, anticonvulsants, antidepressants, antispastic drugs, NSAIDs and other cerebral palsy medications. Many international and regional cerebral palsy therapeutic companies are vying for their share of the market, and the new players must differentiate themselves to gain vital traction over their peers.

This report offers a complete analysis of several cerebral palsy therapeutic companies, including:

• Allergan
• GlaxoSmithKline
• Johnson & Johnson
• Pfizer

We can help! Our analysts can customize this report to meet your requirements. Get in touch